Company news
Theralase Technologies Inc. (TSXV:TLT) news
Theralase Technologies Inc. news releases on 6ix. Latest, Aug 29, 2019: Theralase Releases Second Quarter 2019 Financial Results and Company Update
Press releases — page 4
Theralase Releases Second Quarter 2019 Financial Results and Company Update
August 29, 2019
Theralase Announces Closing of Prospectus Offering for Gross Proceeds of $17,250,000
August 22, 2019
Theralase Announces Pricing Of Prospectus Offering
August 1, 2019
Patient Five Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
July 31, 2019
McGill University Health Centre Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
July 30, 2019
Theralase Enrolls First Patient into Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
July 29, 2019
Theralase Signs Agreement with Urology Organization to Provide US Clinical Study Sites for its Phase II Non Muscle Invasive Bladder Cancer Clinical Study
July 24, 2019
Theralase Receives Notice of Acceptance for Multiwavelength Photo Dynamic Therapy from Russian Patent Office
July 16, 2019
Theralase Releases 2019 Annual General Meeting Video Presentations
June 28, 2019
Regulatory Updates from Health Canada and US FDA
June 27, 2019
Theralase Files Prospectus for Offering of Units
June 26, 2019
Health Canada Approves Amended Clinical Trial Application
June 26, 2019
Theralase Brain Cancer Pre-Clinical Research Accepted for Publication
June 25, 2019
Theralase Releases Amended and Restated 1Q2019 Financial Statements
June 18, 2019
Voltaic Minerals Corp. Receives Conditional TSXV Acceptance for Binding Letter of Intent with 1146915 B.C. Ltd.
June 14, 2019
Theralase Releases 1Q 2019 Financial Statements
May 30, 2019
Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office
May 20, 2019
Theralase's 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
May 13, 2019
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
May 7, 2019
Theralase's Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association
May 6, 2019
Theralase Commences Phase II NMIBC Clinical Study
April 25, 2019
Theralase's Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress
April 22, 2019
Theralase(R) Releases 2018 Year End Audited Financial Statements
April 17, 2019
Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment
April 2, 2019
Theralase's Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World Congress
March 26, 2019
Theralase Granted United States Patent to Destroy Cancer Cells with X-Ray Activated Photo Dynamic Compounds
March 4, 2019
Theralase Named to 2019 TSX Venture 50(TM)
February 28, 2019
Theralase Announces Appointment of New Chief Executive Officers
February 25, 2019
Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment
January 31, 2019
Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment
January 30, 2019
Theralase(R) Completes $1.4 M Private Placement Equity Financing
January 9, 2019
Health Canada Grants ITA Approval to Commence Phase II Clinical Study
December 10, 2018
Theralase's Rutherrin(R) Photo Dynamic Therapy Induces Immune Response to Destroy Human Brain Cancer Cells
November 30, 2018
Theralase Release 3Q2018 Financial Statements
November 29, 2018
Theralase(R) Granted Canadian Anti-Cancer Patent
November 15, 2018
Patient Five Cancer-Free After Single PDT Treatment
November 8, 2018
Theralase® Anti-Cancer Technology Shows Promise for Esophageal Cancer Using Targeted Molecular Delivery System
October 9, 2018
Theralase Announces Completion of Non-Brokered Private Placement for Approximately $1.1 million
October 3, 2018
Health Canada Approves Commencement of Phase II Clinical Study
September 10, 2018
Theralase's Lead Photodynamic Compound TLD-1433 Provides New Opportunities in Targeted Cancer Therapy
September 4, 2018
Theralase Announces Proposed Non-Brokered Private Placement of up to $10 Million
August 28, 2018
Theralase® Provides Update on Upcoming Initiatives for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
August 27, 2018
Theralase Submits Phase II Bladder Cancer Clinical Study Application to Health Canada for Review and Approval
August 20, 2018
Theralase Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five and Six
August 13, 2018
Theralase Release 2Q2018 Financial Statements
July 26, 2018
BTV Reveals Novel Cancer Treatment, Cannabis and Lithium Companies
July 26, 2018
Theralase Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment
July 16, 2018
Theralase Releases AGM Videos
June 29, 2018
Theralase Researchers Receive Government Grant
June 28, 2018
Theralase Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin® Based Photo Dynamic Therapy, in Immune Privileged Sites
June 22, 2018